Probiotics Clinical Trial
Official title:
Change in Human Gut Flora and in Immune Functions Following Probiotic Administration
Healthy human gut contains a large number of bacteria, which belong to several different
species. Some genes in these bacteria encode enzymes that the human body cannot produce.
These enzymes can catalyze metabolic reactions in the distal small bowel. For instance,
bacterial enzymes can breakdown indigestible dietary constituents, making available extra
energy to the host. The current paradigm treats the human body as a 'metagenome', i.e. a
composite of Homo sapiens genes and genes in the genomes of the colonizing bacteria.
Till recently, accurate determination of bacterial gut flora was not possible. Recent
development of multi-parallel sequencing techniques has allowed unbiased determination of
profile of gut flora. These techniques have revealed changes in gut flora in several disease
conditions, including those of the gastrointestinal tract and liver. This has prompted the
use of drugs, such as probiotics to restore the gut flora.
Probiotics contain living microorganisms, and are administered in an attempt to obtain health
benefits by restoring normal gut flora. These preparations provide benefit to patients with
several diseases, including childhood diarrhea, antibiotic-associated diarrhea, inflammatory
bowel disease, vaginitis, etc. However, the mechanisms of their beneficial effects remains
unclear. Gut microbiota appear to modulate the development of immune system and maintain a
balance between Th17 and T regulatory cells in animals. However, it is not known whether
administration of probiotics changes the profile (nature and relative density of various
species) of gut flora, and whether these changes are short-lasted or persistent.
This proposal aimed to study whether probiotic administration influences the gut bacterial
profile and host immune responses. In addition, we wished to determine whether the changes in
gut flora and immune responses persist after probiotic administration is stopped.
Study Subjects The study included 14 healthy non-pregnant women. All subjects provided a
written informed consent. The subjects had to (i) be free of systemic (diabetes, autoimmune
disease, cancer), gastrointestinal or liver diseases that are known to be associated with
alterations in intestinal flora, (ii) be non-obese (body mass index in the range of 20 to 25
Kg/m2), and (iii) not have taken any anti-microbial agent, probiotics, gastric acid
suppressant drugs or drugs that alter gastrointestinal motility, in the previous 6 weeks.
Study design Each subject was studied at 3 time points: (i) baseline (enrolment), (ii) after
administration of a probiotic in usual dose for four weeks, and (iii) four weeks after
discontinuation of probiotic administration. Each subject received Cap VSL#3, 2 capsules
daily (each capsule contains 112.5 billion bacteria -- a mixture of 8 bacteria --
Streptococcus thermophilus, Bifido-bacterium breve, Bifidobacterium longum, Bifidobacterium
infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, and
Lactobacillus delbrueckii). At each time point, gut microbiota profile and immune responses
were studied.
Metagenomic study for analysis of gut flora Analysis for identification and profiling of gut
microflora was done using sequencing of V3 region of the 16S ribosomal ribonucleic acid gene.
This gene contains nine variable regions flanked by conserved stretches in all bacteria.
Amplification and sequencing of any hypervariable region using specific primers can be used
to determine the nature of the bacterium (phylum, family, genus, species, etc). The most
widely used regions are V3, V4 and V6; we used V3 region, due to its higher taxonomic
resolution.
Stool specimen were collected from subjects at 3 time points as indicated above by asking the
subject to pass stool into a clean sterile receptacle; the receptacle was immediately frozen
and transported to the laboratory. DNA was isolated from each specimen using standard
protocols, quantified, normalised and stored frozen until further use.
Polymerase chain reaction amplification of V3 region was done. Gel-purified amplicons (with
different adapter sequences so that data for each sample can be separated at analysis stage)
were quantified, normalised and pooled in equimolar quantities (multiplexing). The
multiplexed library was subjected to quality control using an Agilent Bioanalyser DNA Chip.
The sequencing library containing V3 amplicons from an equi-amount mixture of various
clinical samples was sequenced using an Illumina machine in both directions. The sequence
reads were binned according to index sequences, subjected to quality control and sequences in
the two directions were fused together to obtain a single read. The sequence data were
analysed to determine the profile of gut flora.
Immunological studies Collection of blood specimens Venous blood (6 ml) was collected in
lithium heparin/EDTA, at (i) baseline (before starting probiotic administration), (ii) at the
end of probiotic treatment (at 4 weeks), and (iii) at 4 weeks after discontinuation of
probiotic intake. From 2.5 ml of blood, plasma was separated and stored at -70 degree
centigrade. The remaining heparinized blood was used for whole blood culture and for
measurement of frequencies of Th17 and Treg cells.
Heparinized blood was used and anti-CD28 (1 ug/ml) for stimulation of T cells and
lipopolysaccharide for stimulation of macrophages, in separate wells. Culture supernatants
were harvested after 72 hours and stored at -70 degree centigrade. Levels of cytokines
(TNF-alpha, IL-10, IFN-gamma, IL-12p70, IL-6 and IL-4) were measured in culture supernatant
and plasma using sandwich ELISAs.
Th1, Th2 and Th17 frequencies were determined by stimulation of whole blood with PMA and
ionomycin, followed by staining of cells for CD4 and intracellular IFN, IL-4 and IL-1L-17.
For Treg enumeration, dual staining for CD4 and Fox-P3 was done.
Ethics considerations The study involves administration of probiotics to healthy subjects.
However, these contain bacteria that are a part of the normal gut flora in healthy persons
and hence free of any adverse events. In fact, several healthy persons consume these as
'health supplements'. Hence, the administration of these agents should not carry more than
minimal risk. The only specimens proposed to be collected are stool specimens and small
volumes of blood. No clinical outcomes was collected.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03586622 -
One Year Home Monitoring and Treatment of IBS Patients
|
N/A | |
Recruiting |
NCT06323642 -
Role of Probiotics as Adjunct Therapy Along With Standard Care in Decreasing Hospital Stay and Improving Symptoms in Pediatric Patients Admitted With Severe Pneumonia
|
N/A | |
Completed |
NCT03556631 -
Effect of Live Combined Bifidobacterium and Lactobacillus on Glycemic Control and Other Outcomes in Type 1 Diabetes
|
Phase 4 | |
Completed |
NCT04289337 -
Double-blind Clinical Trials of Probiotic Products in Oral Health.
|
N/A | |
Completed |
NCT04043000 -
Super 13 Pro & Prebiotics on the Human Intestinal Microflora
|
N/A | |
Not yet recruiting |
NCT03967301 -
Prevention and Decolonization of Multidrug-resistant Bacteria With Probiotics
|
N/A | |
Completed |
NCT02207140 -
Effect of Multi-species Probiotic HOWARU® Restore, on Gut Microbiota of Elderly
|
Phase 0 | |
Completed |
NCT01201577 -
Biological Modulation of Bacterial QSSMs, Innate and Adaptive Immunity by Antibiotics, Probiotics and Prebiotics in Healthy Individuals
|
Phase 1 | |
Not yet recruiting |
NCT06063226 -
Clinical and Microbiological Aspects of Probiotics in Non-surgical Periodontal Therapy.
|
N/A | |
Recruiting |
NCT05588674 -
The Effect of Probiotics on Exercise Performance and Recovery
|
N/A | |
Completed |
NCT05798689 -
Use of a Selected Mixture of Probiotic Strains for Degrading Gluten During Digestion
|
N/A | |
Completed |
NCT03167593 -
Effects of Lactobacillus Coryniformis CECT5711 on Immune Response to Influenza Vaccination in Adults Over 65.
|
Phase 2 | |
Completed |
NCT05073393 -
Effect of Probiotics on Oral Homeostasis During Sugar Stress
|
N/A | |
Completed |
NCT02971787 -
Salt Intake and Lactobacillus Abundance
|
N/A | |
Recruiting |
NCT02005003 -
Cognitive and Metabolic Effects of a Probiotic Supplement
|
N/A | |
Recruiting |
NCT05657730 -
Study the Effect of Water Kefir Consumption on the Gut Microbiome in Healthy Adults
|
N/A | |
Completed |
NCT03499184 -
Adjunctive Probiotics in Chronic Periodontitis
|
N/A | |
Enrolling by invitation |
NCT04527055 -
The Efficacy of 10-day and 14-day Bismuth-based Quadruple Therapy in First-line H. Pylori Eradication
|
Phase 4 | |
Recruiting |
NCT05005611 -
Probiotics Regulates Skin Care in Children
|
N/A | |
Recruiting |
NCT05337670 -
Probiotics Regulates Skin Care in Children
|
N/A |